Ovid Therapeutics Named Top Pick by B. Riley on Pipeline Catalysts

B. Riley has reiterated its Buy rating on Ovid Therapeutics, Inc. (OVID), designating the company as a top pick in the pharmaceutical sector. The firm's positive outlook follows a recent discussion with Ovid CEO Meg Alexander at the B. Riley MMV Summit.

Key Catalysts Identified

According to B. Riley's analysis, Ovid's stock has multiple potential catalysts expected between late 2026 and early 2027. The brokerage identified three primary drivers that could significantly appreciate the company's valuation.

• OV329 Epilepsy Program: The firm anticipates topline data from an open-label study by year-end 2026, which would provide the first patient-level efficacy signal. Further Phase 2a data in mid-2027 will address what B. Riley estimates is a $1 billion market opportunity for the adult formulation.
• Pediatric Formulation: A separate liquid version for pediatric use could secure a standalone orphan drug indication. This development has the potential to expand the total market opportunity for OV329 to approximately $2 billion.
• KCC2 Platform: B. Riley believes Ovid's wholly-owned KCC2 platform currently receives no valuation from the market. The firm expects ketamine challenge data in late 2026 or early 2027 to be the first major event to assign value to this franchise.

Analyst's Perspective

Despite Ovid's stock gaining 39% year-to-date and outpacing the XBI biotech index's 27% rise, B. Riley considers the risk-reward profile to be compelling. The firm noted that the KCC2 modulation mechanism is potentially superior to existing GABA-A pharmacology, as it may avoid common side effects like sedation, cognitive impairment, and dependence.

Ad

This assessment underscores the potential for Ovid's pipeline to address unmet needs in neurological treatments. The upcoming data readouts are seen as critical milestones that could unlock significant value for investors.

Financial and Corporate Health

Ovid Therapeutics is well-capitalized to pursue its clinical goals, with cash resources projected to last into 2029. This financial runway is sufficient to fund four to six proof-of-concept data readouts, providing multiple opportunities for value creation through 2027.

In recent corporate developments, Ovid reported first-quarter results that met analyst expectations, made several executive appointments, and announced progress in its pipeline, including dosing the first participant in its OV4071 study.